Pfizer puts up $1bn to buy into Arvinas breast cancer programmePfizer has pledged a whopping $1 billion upfront for rights to an Arvinas drug for breast cancer from Share XPfizer puts up $1bn to buy into Arvinas breast cancer programmehttps://pharmaphorum.com/news/pfizer-puts-up-1bn-to-buy-into-arvinas-breast-cancer-programme/
ASCO21: Lynparza aces adjuvant breast cancer therapy trialAstraZeneca and Merck & Co’s Lynparza is primed for even wider use in the treatment of breast cancer Share XASCO21: Lynparza aces adjuvant breast cancer therapy trialhttps://pharmaphorum.com/news/asco21-lynparza-aces-adjuvant-breast-cancer-therapy-trial/
AZ/Daiichi unveil data from TNBC hopeful datopotamab deruxtecanAstraZeneca and Daiichi Sankyo have revealed new data from datopotamab deruxtecan in triple negative breast cancer (TNBC) – Share XAZ/Daiichi unveil data from TNBC hopeful datopotamab deruxtecanhttps://pharmaphorum.com/news/az-daiichi-unveil-data-from-tnbc-hopeful-datopotamab-deruxtecan/
Tecentriq can stay as therapy for triple-negative breast cancer, FDA experts sayRoche’s Tecentriq can stay on the US market as a therapy for triple negative breast cancer, advisers to Share XTecentriq can stay as therapy for triple-negative breast cancer, FDA experts sayhttps://pharmaphorum.com/news/tecentriq-can-stay-as-therapy-for-triple-negative-breast-cancer-fda-experts-say/
Enhertu cleared for NHS use via Cancer Drugs FundNICE has recommended the use of AstraZeneca and Daiichi Sankyo’s Enhertu in draft guidance, the first time the Share XEnhertu cleared for NHS use via Cancer Drugs Fundhttps://pharmaphorum.com/news/enhertu-cleared-for-nhs-use-via-cancer-drugs-fund/
Gilead scores US approval for breast cancer drug that wowed ESMOGilead’s $21 billion purchase of Immunomedics and its potential blockbuster Trodelvy continues to pay off, as the drug Share XGilead scores US approval for breast cancer drug that wowed ESMOhttps://pharmaphorum.com/news/gilead-scores-us-approval-for-breast-cancer-drug-that-wowed-esmo/
NICE okays regular NHS funding for Novartis’ breast cancer drug KisqaliNICE has recommended moving Novartis’ Kisqali (ribociclib) from interim funding arrangements to regular NHS reimbursement for certain previously Share XNICE okays regular NHS funding for Novartis’ breast cancer drug Kisqalihttps://pharmaphorum.com/news/nice-okays-regular-nhs-funding-for-novartis-breast-cancer-drug-kisqali/
Filing beckons as Lynparza hits the mark in adjuvant breast cancerAstraZeneca’s PARP inhibitor Lynparza has shown a clinical benefit when given as an adjuvant for early breast cancer, Share XFiling beckons as Lynparza hits the mark in adjuvant breast cancerhttps://pharmaphorum.com/news/filing-beckons-as-lynparza-hits-the-mark-in-adjuvant-breast-cancer/
MacroGenics’ HER2 breast cancer drug Margenza approved in USMacroGenics’ HER2-targeted breast cancer drug Margenza has been approved by the FDA, challenging several recently approved drugs with Share XMacroGenics’ HER2 breast cancer drug Margenza approved in UShttps://pharmaphorum.com/news/macrogenics-her2-breast-cancer-drug-margenza-approved-in-us/
